161 related articles for article (PubMed ID: 18331669)
21. Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder.
Leelahanaj T
J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S35-42. PubMed ID: 21284135
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States.
Beard SM; Roskell N; Le TK; Zhao Y; Coleman A; Ang D; Lawson K
J Med Econ; 2011; 14(4):463-76. PubMed ID: 21651426
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada.
Iskedjian M; Walker JH; Bereza BG; Le Melledo JM; Einarson TR
Curr Med Res Opin; 2008 May; 24(5):1539-48. PubMed ID: 18416886
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and cost-effectiveness of transmural collaborative care with consultation letter (TCCCL) and duloxetine for major depressive disorder (MDD) and (sub)chronic pain in collaboration with primary care: design of a randomized placebo-controlled multi-Centre trial: TCC:PAINDIP.
de Heer EW; Dekker J; van Eck van der Sluijs JF; Beekman AT; van Marwijk HW; Holwerda TJ; Bet PM; Roth J; Hakkaart-Van Roijen L; Ringoir L; Kat F; van der Feltz-Cornelis CM
BMC Psychiatry; 2013 May; 13():147. PubMed ID: 23705849
[TBL] [Abstract][Full Text] [Related]
25. Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.
Vataire AL; Aballéa S; Antonanzas F; Roijen LH; Lam RW; McCrone P; Persson U; Toumi M
Value Health; 2014 Mar; 17(2):183-95. PubMed ID: 24636376
[TBL] [Abstract][Full Text] [Related]
26. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
Bellows BK; Dahal A; Jiao T; Biskupiak J
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):153-64. PubMed ID: 22509775
[TBL] [Abstract][Full Text] [Related]
27. [Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain].
Rejas Gutiérrez J; Blanca Tamayo M; Gascón Barrachina J; Armada Peláez B
Rev Psiquiatr Salud Ment; 2016; 9(2):87-96. PubMed ID: 26475204
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
Nguyen KH; Gordon LG
Value Health; 2015 Jul; 18(5):597-604. PubMed ID: 26297087
[TBL] [Abstract][Full Text] [Related]
29. The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.
Wielage RC; Bansal M; Andrews JS; Wohlreich MM; Klein RW; Happich M
Value Health; 2013; 16(2):334-44. PubMed ID: 23538186
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.
van Baardewijk M; Vis PM; Einarson TR
Curr Med Res Opin; 2005 Aug; 21(8):1271-9. PubMed ID: 16083537
[TBL] [Abstract][Full Text] [Related]
31. Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom.
Young AH; Evitt L; Brignone M; Diamand F; Atsou K; Campbell R; Cure S; Danchenko N
J Affect Disord; 2017 Aug; 218():291-298. PubMed ID: 28478358
[TBL] [Abstract][Full Text] [Related]
32. Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms.
McIntyre RS; Konarski JZ
Expert Opin Pharmacother; 2005 May; 6(5):707-13. PubMed ID: 15934897
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
Fernandez JL; Montgomery S; Francois C
Pharmacoeconomics; 2005; 23(2):155-67. PubMed ID: 15748090
[TBL] [Abstract][Full Text] [Related]
34. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
Leelahanaj T
J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine.
Cui Z; Faries DE; Shen W; Able SL; Novick D
J Med Econ; 2013; 16(5):623-32. PubMed ID: 23425292
[TBL] [Abstract][Full Text] [Related]
36. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.
Maniadakis N; Kourlaba G; Mougiakos T; Chatzimanolis I; Jonsson L
BMC Health Serv Res; 2013 May; 13():173. PubMed ID: 23663281
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model.
Ramsberg J; Asseburg C; Henriksson M
PLoS One; 2012; 7(8):e42003. PubMed ID: 22876296
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
[TBL] [Abstract][Full Text] [Related]
39. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
Cui Z; Faries DE; Zhao Y; Novick D; Liu X
J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
[TBL] [Abstract][Full Text] [Related]
40. Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
Ye W; Zhao Y; Robinson RL; Swindle RW
BMC Psychiatry; 2011 Jan; 11():19. PubMed ID: 21281479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
